AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company focused on the development of botulinum toxin-based therapeutic products targeting therapeutic and medical aesthetics markets. The company reached the public markets through a business combination with Priveterra Acquisition Corp, a blank-check SPAC sponsored by Priveterra Acquisition Holdings. The amended quarterly report, Form 10-Q/A, filed on March 3, 2022, reflects an amendment to a prior quarterly disclosure as the company navigated its public reporting obligations within the healthcare and life sciences sector. AEON operates in a specialized segment of the biopharmaceutical space, with its pipeline centered on neuromodulator applications. Sign up at SpacDesk for complete filing history, sponsor profiles, and real-time deal data on AEON and hundreds of other SPAC transactions.